Wedbush Reconfirms Omeros (NASDAQ:OMER) As a Neutral; They Now Have a Target Price per Share Of $20

May 17, 2018 - By Bradley Stiles

Omeros Corporation (NASDAQ:OMER) Logo

Investors sentiment decreased to 1.3 in 2017 Q4. Its down 1.56, from 2.86 in 2017Q3. It turned negative, as 14 investors sold Omeros Corporation shares while 29 reduced holdings. 31 funds opened positions while 25 raised stakes. 21.94 million shares or 0.43% less from 22.04 million shares in 2017Q3 were reported.

Blackrock stated it has 3.93 million shares. Tocqueville Asset Limited Partnership invested in 0.06% or 290,119 shares. Trust Department Mb Bank N A accumulated 2,550 shares. Citadel Advsrs Limited Liability Corp owns 31,184 shares or 0% of their US portfolio. Davenport And Communication Limited Co reported 79,400 shares stake. Susquehanna Intll Group Inc Limited Liability Partnership stated it has 1.42 million shares. Victory Capital Mgmt accumulated 0% or 1,570 shares. Cypress Capital Gru holds 0.04% or 10,000 shares. First Advsrs Lp reported 0% stake. Ellington Management Lc stated it has 0.05% of its portfolio in Omeros Corporation (NASDAQ:OMER). National Bank Of New York Mellon holds 217,411 shares. Moreover, Fincl has 1.48% invested in Omeros Corporation (NASDAQ:OMER) for 715,101 shares. Alliancebernstein L P owns 0% invested in Omeros Corporation (NASDAQ:OMER) for 59,100 shares. Stifel holds 0.02% or 342,192 shares in its portfolio. Chicago Equity Ptnrs Limited Liability Co holds 195,120 shares.

Since January 3, 2018, it had 0 buys, and 2 insider sales for $1.36 million activity. Another trade for 1,020 shares valued at $22,899 was sold by JACOBSEN MICHAEL A.

Omeros (NASDAQ:OMER) Rating Reaffirmed

The financial firm has just set a price target of $20 on Omeros (NASDAQ:OMER) shares. This is -1.28 % from the current price. In an analyst report sent to investors on Thursday, 17 May, Wedbush maintained their Neutral rating on shares of OMER.

Omeros Corporation (NASDAQ:OMER) Ratings Coverage

Among 5 analysts covering Omeros Corp (NASDAQ:OMER), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Omeros Corp has $7500 highest and $25 lowest target. $45.25’s average target is 123.35% above currents $20.26 stock price. Omeros Corp had 15 analyst reports since November 28, 2017 according to SRatingsIntel. H.C. Wainwright maintained the shares of OMER in report on Wednesday, April 4 with “Buy” rating. The rating was maintained by WBB Securities with “Buy” on Monday, March 26. The rating was maintained by H.C. Wainwright with “Buy” on Wednesday, November 29. The firm has “Buy” rating by H.C. Wainwright given on Thursday, April 19. Needham downgraded the shares of OMER in report on Friday, March 2 to “Hold” rating. The firm earned “Buy” rating on Tuesday, November 28 by Wedbush. As per Friday, March 23, the company rating was maintained by H.C. Wainwright. On Thursday, December 14 the stock rating was maintained by H.C. Wainwright with “Buy”. The firm earned “Buy” rating on Friday, May 11 by H.C. Wainwright. H.C. Wainwright maintained the shares of OMER in report on Monday, March 5 with “Buy” rating.

The stock increased 1.25% or $0.25 during the last trading session, reaching $20.26. About 1.66M shares traded or 4.48% up from the average. Omeros Corporation (NASDAQ:OMER) has declined 3.39% since May 18, 2017 and is downtrending. It has underperformed by 14.94% the S&P500.

Analysts await Omeros Corporation (NASDAQ:OMER) to report earnings on August, 14. They expect $-0.55 EPS, down 139.13 % or $0.32 from last year’s $-0.23 per share. After $-0.53 actual EPS reported by Omeros Corporation for the previous quarter, Wall Street now forecasts 3.77 % negative EPS growth.

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company has market cap of $978.41 million. The firm markets OMIDRIA for use during cataract surgery or intraocular lens replacement. It currently has negative earnings. The Company’s clinical programs include OMS721 that is in Phase III clinical trial for the treatment of atypical hemolytic uremic syndrome; and in Phase II clinical trial to treat thrombotic microangiopathies, IgA nephropathy, and other renal diseases.

More recent Omeros Corporation (NASDAQ:OMER) news were published by: Fool.com which released: “Why Omeros, Party City Holdco, and Overstock.com Slumped Today” on May 16, 2018. Also Seekingalpha.com published the news titled: “Your Daily Pharma Scoop: Omeros Up On Update, Synergy Sales, President’s Healthcare Plans” on May 14, 2018. Seekingalpha.com‘s news article titled: “Rounds Report: Omeros Rallied Robustly While Stellar FDA Due Diligence To Help Orphan Disease Innovators” with publication date: May 16, 2018 was also an interesting one.

Omeros Corporation (NASDAQ:OMER) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: